Prices of top 25 Medicare Part D drugs have nearly doubled, AARP study finds
AARP's new research finds price growth for top Part D prescription drugs has exceeded inflation, making a case for allowing Medicare to negotiate prices.
Weight-loss drugs like Ozempic may be up for Medicare price negotiations — will Trump support it?
Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face an uncertain future in the incoming Trump administration.
Medicare Drug Price Explanations Shed Some Light on Future Talks
The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and uncertainty about a process largely held behind closed doors, just as another round of talks begin in the coming weeks under a new administration.
Ozempic, Trulicity among Medicare's priciest drugs, report finds
Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet selected for price negotiation, according to a report released Thursday. The report from AARP Public Policy Institute said average list prices on these 25 drugs have nearly doubled since they hit the market and collectively cost Medicare ‒ and American taxpayers ‒ nearly $50 billion in 2022.
New AARP Report: Top Medicare Part D Drugs See Average Lifetime Price Hike of 98%
Findings show the impact of drug companies’ relentless price increases, underscoring the importance of the changes included in the historic 2022 drug law.
Pharma companies welcome new year with 583 drug price hikes so far
Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, 46brooklyn Research, an Ohio non-profit focused on U.S. drug pricing data, said in a report on Thursday.
25 Top Medicare Part D Drugs Have Nearly Doubled in Price
People with Medicare Part D plans shoulder a share of the cost of their prescription drugs. Under the standard Part D benefit, enrollees are responsible for 25 percent of their dr
Medicare rules may reduce prescription steering
Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to ...
Medicare Bills Are Increasing: Here's Who's Impacted
Medicare bills are increasing for millions of Americans despite a $2,000 prescription drug cap beginning in 2025, as premiums ...
Biden ‘finally beat Medicare’ on his way out of office
On its way out, the Biden administration is fighting to limit Medicare Advantage options, leaving the Trump administration with little time to adjust.
Here We Go Again: The Medicare Advantage Open Enrollment Period
The Medicare Advantage Open Enrollment Period (Jan 1–Mar 31) lets you switch plans or adjust coverage. Review your options to ...
Center on Budget and Policy Priorities4h
Growth in Medicare Advantage Raises Concerns
MA plans are substantially overpaid compared to traditional Medicare. Much of these overpayments benefit the MA plans rather ...
Monthly Prescribing Reference5h
Cuts to Medicare Physician Reimbursement Take Effect After Congress Fails to Pass Legislation
For the fifth consecutive year, Congress has adjourned and allowed Medicare cuts,” said Bruce A. Scott, MD, president of the AMA.
Ama-assn.org4h
AMA advocacy efforts for 2025: Fixing Medicare now, prior authorization reform and more [Podcast]
The AMA Update covers a range of health care topics affecting the lives of physicians and patients. Learn more about AMA's advocacy efforts for 2025.
clinicaladvisor.com4h
Medicare Patients Wait Average of 34 Days to See Neurologist After Referral
After being referred by their physician, Medicare patients wait an average of 34 days to see a neurologist, according to a study published online in Neurology.
Mastering Medicare Appeals: Your Guide to Overturning Denials
On the other hand, Medicare Advantage plans have a more nuanced process. These plans require prior approval for all claims, making the insurance carrier the first point of contact for denials. While ...
Study reveals cost differences between Medicare Advantage and traditional Medicare patients in cancer drugs
A new study examining the use of high-cost drugs among patients with colorectal cancer and non-small cell lung cancer found ...